Cargando…

Results of second transurethral resection for high-grade T1 bladder cancer

BACKGROUND: The aim of this study was to examine the histological outcome and potential therapeutic benefit of second transurethral resection (TUR) for high-grade T1 bladder cancer. PATIENTS AND METHODS: The subjects were 171 patients who underwent initial TUR between January 1993 and December 2013,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashine, Katsuyoshi, Ide, Takehiro, Nakashima, Takeshi, Hosokawa, Tadanori, Ninomiya, Iku, Teramoto, Norihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4719498/
https://www.ncbi.nlm.nih.gov/pubmed/26834394
http://dx.doi.org/10.4103/0974-7796.163798
_version_ 1782410942453121024
author Hashine, Katsuyoshi
Ide, Takehiro
Nakashima, Takeshi
Hosokawa, Tadanori
Ninomiya, Iku
Teramoto, Norihiro
author_facet Hashine, Katsuyoshi
Ide, Takehiro
Nakashima, Takeshi
Hosokawa, Tadanori
Ninomiya, Iku
Teramoto, Norihiro
author_sort Hashine, Katsuyoshi
collection PubMed
description BACKGROUND: The aim of this study was to examine the histological outcome and potential therapeutic benefit of second transurethral resection (TUR) for high-grade T1 bladder cancer. PATIENTS AND METHODS: The subjects were 171 patients who underwent initial TUR between January 1993 and December 2013, and were diagnosed with high-grade T1 bladder cancer. Second TUR was performed within 4–6 weeks after the initial resection. Intravesical recurrence, invasive intravesical recurrence, and disease-free, progression-free, and overall survival were examined between second TUR group and no second TUR group. RESULTS: Of the 171 patients, 79 (46.2%) underwent second TUR. Histological findings from second TUR were no cancer in 33 (41.8%), carcinoma in situ in 18 (22.9%), Ta in 15 (19.0%), T1 in 12 (15.2%), and muscle invasive bladder cancer (T2) in 1 case (1.3%). The 5- and 10-year intravesical recurrence-free survival rates were 72.0% and 57.4%, respectively, and the disease-free survival rates at these times were 69.7% and 49.6%, respectively. Second TUR had no influence on intravesical recurrence, regardless of the use of Bacillus Calmette–Guerin (BCG) therapy. No BCG therapy and recurrent cancer were significantly associated with intravesical recurrence in multivariate analysis. Recurrent cancer was also a significant risk factor for invasive intravesical recurrence. BCG therapy significantly improved disease-free survival. Second TUR was a significant factor in overall survival. In the histological results for second TUR, no cancer and Tis cases had reduced intravesical recurrence compared to Ta and T1 cases. CONCLUSION: Second TUR allows more accurate staging and pT0 cases in second TUR have a better outcome, indicating a possible therapeutic benefit of the procedure.
format Online
Article
Text
id pubmed-4719498
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-47194982016-02-01 Results of second transurethral resection for high-grade T1 bladder cancer Hashine, Katsuyoshi Ide, Takehiro Nakashima, Takeshi Hosokawa, Tadanori Ninomiya, Iku Teramoto, Norihiro Urol Ann Original Article BACKGROUND: The aim of this study was to examine the histological outcome and potential therapeutic benefit of second transurethral resection (TUR) for high-grade T1 bladder cancer. PATIENTS AND METHODS: The subjects were 171 patients who underwent initial TUR between January 1993 and December 2013, and were diagnosed with high-grade T1 bladder cancer. Second TUR was performed within 4–6 weeks after the initial resection. Intravesical recurrence, invasive intravesical recurrence, and disease-free, progression-free, and overall survival were examined between second TUR group and no second TUR group. RESULTS: Of the 171 patients, 79 (46.2%) underwent second TUR. Histological findings from second TUR were no cancer in 33 (41.8%), carcinoma in situ in 18 (22.9%), Ta in 15 (19.0%), T1 in 12 (15.2%), and muscle invasive bladder cancer (T2) in 1 case (1.3%). The 5- and 10-year intravesical recurrence-free survival rates were 72.0% and 57.4%, respectively, and the disease-free survival rates at these times were 69.7% and 49.6%, respectively. Second TUR had no influence on intravesical recurrence, regardless of the use of Bacillus Calmette–Guerin (BCG) therapy. No BCG therapy and recurrent cancer were significantly associated with intravesical recurrence in multivariate analysis. Recurrent cancer was also a significant risk factor for invasive intravesical recurrence. BCG therapy significantly improved disease-free survival. Second TUR was a significant factor in overall survival. In the histological results for second TUR, no cancer and Tis cases had reduced intravesical recurrence compared to Ta and T1 cases. CONCLUSION: Second TUR allows more accurate staging and pT0 cases in second TUR have a better outcome, indicating a possible therapeutic benefit of the procedure. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC4719498/ /pubmed/26834394 http://dx.doi.org/10.4103/0974-7796.163798 Text en Copyright: © Urology Annals http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Hashine, Katsuyoshi
Ide, Takehiro
Nakashima, Takeshi
Hosokawa, Tadanori
Ninomiya, Iku
Teramoto, Norihiro
Results of second transurethral resection for high-grade T1 bladder cancer
title Results of second transurethral resection for high-grade T1 bladder cancer
title_full Results of second transurethral resection for high-grade T1 bladder cancer
title_fullStr Results of second transurethral resection for high-grade T1 bladder cancer
title_full_unstemmed Results of second transurethral resection for high-grade T1 bladder cancer
title_short Results of second transurethral resection for high-grade T1 bladder cancer
title_sort results of second transurethral resection for high-grade t1 bladder cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4719498/
https://www.ncbi.nlm.nih.gov/pubmed/26834394
http://dx.doi.org/10.4103/0974-7796.163798
work_keys_str_mv AT hashinekatsuyoshi resultsofsecondtransurethralresectionforhighgradet1bladdercancer
AT idetakehiro resultsofsecondtransurethralresectionforhighgradet1bladdercancer
AT nakashimatakeshi resultsofsecondtransurethralresectionforhighgradet1bladdercancer
AT hosokawatadanori resultsofsecondtransurethralresectionforhighgradet1bladdercancer
AT ninomiyaiku resultsofsecondtransurethralresectionforhighgradet1bladdercancer
AT teramotonorihiro resultsofsecondtransurethralresectionforhighgradet1bladdercancer